Nature Research Round Table: Maintenance of Human Pluripotent Stem Cells In Vitro
Dr. Tenneille Ludwig from the WiCell Research Institute provides information on in vitro culture systems for ES and iPS cell maintenance. The WiCell Research Institute is widely known for their human pluripotent stem cell (hPSC) banking services, with over 1,350 cell lines available to researchers around the globe. This presentation and the following Q&A session were moderated by Dr. Ludovic Vallier from the Wellcome Trust Sanger Institute.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Data Quality and Standards for Pluripotent Stem Cells
In this recorded webinar, Dr. Andreas Kurtz from the BCRT discusses the data and quality standards around human pluripotent stem research including cell line accessibility, ethical considerations, and more.
Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung Cancer
In this webinar, Scientist Vimal Keerthi discusses his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR-Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He demonstrates the feasibility of this CAR T manufacturing platform and how this provides a blueprint for immediate clinical translation, overcoming the bottleneck of viral vector production.
Scaling Biomimetic Culture of Pluripotent Stem Cells
Hear from Dr. Maxime Feyeux, who discusses what the in vivo growth environment of pluripotent stem cells (PSCs) can teach us about in vitro culture. He summarizes some of the current challenges facing standard PSC culture technologies and shares a solution for mass producing high-quality PSCs for downstream applications.
Nature Research Round Table: Retinal Cell Therapy Using Human Embryonic Stem Cells
Dr. Peter Coffey from University College London shares his work with the London Project to Cure Blindness, which resulted in the first clinical stem cell trial to treat blindness, and discusses cell quality requirements for clinical trials. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Note: Some original data from this presentation has been omitted to abide by copyright rules.
Therapeutic Application of Endothelial Colony-Forming Cells for Retinal Diseases
In this webinar, Drs. Susumu Sakimoto and Valentina Marchetti discuss their current research on generating human endothelial colony-forming cells (ECFCs) under xeno-free conditions to treat vascular abnormalities in the eye. Vascular abnormalities are a common component of eye diseases that often lead to vision loss. It is possible to use one cell type to rescue another cell type in the face of severe stress. Dr. Susumu will present his study on how human ECFCs injected into the vitreous cavity rescue vaso-obliteration and neurodegeneration in animal models of retinal disease. These results help us understand the mechanism of ECFC-based therapies for ischemic insults and retinal neurodegenerative diseases. Dr. Valentina Marchetti will present a workflow to derive and expand ECFCs under xeno-free conditions using the EC-Cult™-XF ECFC Culture Kit.
EasySep™小鼠TIL（CD45）正选试剂盒
How to Detect and Isolate Normal and Cancer Stem Cells Based on ALDH Activity with ALDEFLUOR™ An innovative, antibody-free system to rapidly identify stem and progenitor cells of several tissue types, including a variety of cancer stem cells
A Guide to Passaging Human Pluripotent Stem Cells Using mTeSR™1 A guide to passaging human pluripotent stem cells using mTeSR™1
Nature Research Round Table: Maintenance of Human Pluripotent Stem Cells In Vitro Dr. Tenneille Ludwig from the WiCell Research Institute provides information on in vitro culture systems for ES and iPS cell maintenance. The WiCell Research Institute is widely known for their human pluripotent stem cell (hPSC) banking services, with over 1,350 cell lines available to researchers around the globe. This presentation and the following Q&A session were moderated by Dr. Ludovic Vallier from the Wellcome Trust Sanger Institute.
Data Quality and Standards for Pluripotent Stem Cells In this recorded webinar, Dr. Andreas Kurtz from the BCRT discusses the data and quality standards around human pluripotent stem research including cell line accessibility, ethical considerations, and more.
How to Prepare a Single Cell Suspension from Frozen Samples and Prevent Cell Clumping Learn how to harvest cells from a frozen starting sample and prepare a single cell suspension prior to performing cell isolation
How to Isolate Cells in 96-Well Plates Using the EasyPlate™ Cell Separation Magnet Learn how to isolate highly purified, untouched cells in as little as 25 minutes in a convenient format for downstream analysis
Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung Cancer In this webinar, Scientist Vimal Keerthi discusses his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR-Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He demonstrates the feasibility of this CAR T manufacturing platform and how this provides a blueprint for immediate clinical translation, overcoming the bottleneck of viral vector production.
Scaling Biomimetic Culture of Pluripotent Stem Cells Hear from Dr. Maxime Feyeux, who discusses what the in vivo growth environment of pluripotent stem cells (PSCs) can teach us about in vitro culture. He summarizes some of the current challenges facing standard PSC culture technologies and shares a solution for mass producing high-quality PSCs for downstream applications.
Nature Research Round Table: Retinal Cell Therapy Using Human Embryonic Stem Cells Dr. Peter Coffey from University College London shares his work with the London Project to Cure Blindness, which resulted in the first clinical stem cell trial to treat blindness, and discusses cell quality requirements for clinical trials. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center.
Therapeutic Application of Endothelial Colony-Forming Cells for Retinal Diseases In this webinar, Drs. Susumu Sakimoto and Valentina Marchetti discuss their current research on generating human endothelial colony-forming cells (ECFCs) under xeno-free conditions to treat vascular abnormalities in the eye. Vascular abnormalities are a common component of eye diseases that often lead to vision loss. It is possible to use one cell type to rescue another cell type in the face of severe stress. Dr. Susumu will present his study on how human ECFCs injected into the vitreous cavity rescue vaso-obliteration and neurodegeneration in animal models of retinal disease. These results help us understand the mechanism of ECFC-based therapies for ischemic insults and retinal neurodegenerative diseases. Dr. Valentina Marchetti will present a workflow to derive and expand ECFCs under xeno-free conditions using the EC-Cult™-XF ECFC Culture Kit.
